Back to search

University of Glasgow

Proton pump inhibitor co-prescription and hospitalisation risk in patients receiving cardiovascular medications: a real-world observational study

Abstract

dc:description.abstract

Background: Cardiovascular disease remains the leading cause of global mortality and commonly requires long-term pharmacotherapy with anticoagulants, antiplatelet agents and cardiac glycosides. Proton pump inhibitors (PPIs) are among the most frequently co-prescribed medications in these populations, both for gastroprotection during antithrombotic therapy and for concurrent acid-related disease. PPIs have well-characterised pharmacokinetic interactions with cardiovascular drugs through cytochrome P450 inhibition, alterations in gastric pH, and modulation of P-glycoprotein. However, the extent to which these mechanistic interactions translate into clinically meaningful harm in routine care remains uncertain, and existing observational evidence is heterogeneous and susceptible to confounding by indication. Aim: This thesis investigated whether co-prescription of PPIs with three classes of cardiovascular medications -digoxin, oral anticoagulants (warfarin, dabigatran, and factor Xa inhibitors) and clopidogrel - is associated with measurable changes in hospitalisation risk in a large, real-world population, and whether such risks differ by drug class. Methods: Three retrospective cohort studies were conducted using linked electronic health records from NHS Greater Glasgow and Clyde, accessed through the West of Scotland Safe Haven (1 January 2014 – 31 December 2020). Adults aged ≥51 years with relevant index conditions were followed for up to two years. Drug exposure was modelled as a time-varying covariate across four mutually exclusive categories (no exposure, index drug only, PPI only, concurrent exposure), with a 7-day carry-over applied after each prescription. Hazard ratios (HRs) for arrhythmia-related hospitalisation (digoxin cohort), bleeding and treatment failure (oral anticoagulant cohorts), and bleeding-related hospitalisation (clopidogrel cohort) were estimated using time-dependent Cox proportional hazards models within an inverse probability of treatment weighting (IPTW) framework. Simon–Makuch survival curves were used for complementary visualisation, and reporting followed STROBE guidelines. Results: In the digoxin cohort (n=23,351), concurrent digoxin–PPI exposure was associated with a modest but significant increase in arrhythmia-related hospitalisation (HR 1.20, 95% CI 1.03–1.39; p=0.023), whereas digoxin and PPI monotherapies were close to the null. The oral anticoagulant findings varied markedly by class. Concurrent warfarin–PPI exposure was associated with elevated bleeding risk (HR 2.13, 95% CI 1.25–3.63; p=0.005; n=29,765). For dabigatran (n=30,985), concurrent exposure was associated with increased treatment failure (HR 1.71, 95% CI 1.10–2.66; p=0.018), while the bleeding analysis could not be reliably estimated owing to sparse concurrent exposure. Factor Xa inhibitor cohorts (n=27,713) showed lower bleeding risk with concurrent PPI use (HR 0.55, 95% CI 0.43–0.69; p<0.001) and a neutral effect on treatment failure (HR 0.99, 95% CI 0.90–1.08; p=0.785). In post-stroke patients receiving clopidogrel (n=8,109), concurrent PPI use was not associated with bleeding-related hospitalisation (HR 0.83, 95% CI 0.53–1.30; p=0.415). Across all three studies, PPI monotherapy showed no association with adverse outcomes. Conclusions: The effect of PPI co-prescription on clinical outcomes differs by cardiovascular drug rather than acting uniformly. Concurrent use was associated with a modest increase in arrhythmia risk with digoxin and a higher bleeding risk with warfarin, but no increased risk with clopidogrel or factor Xa inhibitors. PPI use on its own was not associated with harm in any cohort. These findings support tailoring monitoring and drug choice to the specific cardiovascular agent, rather than avoiding PPI co-prescription altogether in patients who need gastroprotection.

Degree

thesis:*
Level dc:type.qualificationlevel
PhD
Grantor dc:publisher.institution
University of Glasgow
Year dc:date.issued
2026

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Qadhi, Rawabi Sohiel

Subjects

dc:subject × 2

Rights

Language dc:language
en

Identifiers

dc:identifier.*

Chain of custody

source
Harvested from
University of Glasgow
Base URL
theses.gla.ac.uk/cgi/oai2
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
citation

Qadhi, Rawabi Sohiel. Proton pump inhibitor co-prescription and hospitalisation risk in patients receiving cardiovascular medications: a real-world observational study. PhD thesis, University of Glasgow, 2026. https://doi.org/10.5525/gla.thesis.86310